Virtually Painless Blood Sample Collection Device to Revolutionize Diagnostic Testing
|
By LabMedica International staff writers Posted on 07 Nov 2023 |

The discomfort and inconvenience of traditional blood sampling methods like venipuncture and fingersticks, along with a surge in the need for diagnostics that can be performed outside of traditional healthcare settings, have led to the creation of diagnostic tests that only require minimal blood or interstitial fluid volumes. The process of drawing ample amounts of blood using lancets for testing is often a barrier to testing, especially for certain groups of patients. Furthermore, the lack of standardization in fingerstick blood collection, specifically in the techniques of squeezing the finger and the timing of collection and testing, can vary the quality of the blood sample, affecting the test outcomes. Additionally, it's often difficult to gather a substantial volume of blood (at least 200 microliters) from a fingerstick. Now, an innovative method is making the blood collection process more humane, offering benefits for diagnostic and wellness tests administered at clinical labs or at home by patients themselves.
YourBio Health’s (Boston, MA, USA) 'Touch-Activated Phlebotomy' (TAP) is designed for virtually painless whole capillary blood collection using devices incorporating patented technology. The technology overcomes the drawbacks of conventional blood collection by enabling the gathering of a capillary blood sample from any location on the body, eliminating the discomfort caused by fingersticks or traditional phlebotomy. TAP utilizes microneedles finer than an eyelash, making it less painful than both fingerstick methods and venipuncture, as well as other competing devices.
The TAP Micro Select device for blood collection is designed to yield high-quality and high-volume blood samples that are compatible with standard laboratory processing. Having been subjected to testing with hundreds of thousands of patients, this device consistently collects over 200 microliters of blood in more than 92% of attempts. YourBio Health does not perform the tests but owns the patents for these groundbreaking devices. In addition, the company offers a suite of ancillary services like sample tracking, which can be tailored to support a wide array of clinical trials and high-standard blood sampling for wellness purposes. YourBio Health has received further regulatory approval for its TAP Micro Select blood collection device with certification for CE Marking.
"With our patented Halo technology within the TAP micro series of blood collection devices, YourBio Health is unique in offering virtually painless blood sample collection using a bladeless microneedle array. Regulatory approval will enable our device's use with commercial blood collection tubes and allow use in kits that revolutionize blood testing in diagnostics and wellness," said Harry Wilcox, Chief Executive Officer of YourBio Health. "This additional regulatory clearance will further support the trend in decentralized clinical trials and recruitment and maintenance of more diverse patient populations that are known to be more relevant with certain diseases, which will inevitably lead to successes with much needed new treatments, as well as access to treatments for currently underserved and voluntarily unwilling patient groups."
Related Links:
YourBio Health
Latest Pathology News
- Study Reveals Moleclar Mechanism Driving Aggressive Skin Cancer
- AI Precision Tests Deliver Cancer Risk Insights from Routine H&E Slides
- Collaboration Applies AI Pathology to Predict Response to Antibody-Drug Conjugates
- Biomarker Predicts Immunotherapy Response and Prognosis in Colorectal Cancer
- AI Improves Completeness of Complex Cancer Pathology Reports
- AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
- Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
- AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
- AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
- Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
- New Chromogenic Culture Media Enable Rapid Detection of Candida Infections
- AI-Powered Tool to Transform Dermatopathology Workflow
- AI Tool Predicts Chemotherapy Response from Biopsy Slides
- Sex Differences in Alzheimer’s Biomarkers Linked to Faster Cognitive Decline
- World’s First Optical Microneedle Device to Enable Blood-Sampling-Free Clinical Testing
- Novel mcPCR Technology to Transform Testing of Clinical Samples
Channels
Clinical Chemistry
view channel
Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation
Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more
Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms
Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read moreMolecular Diagnostics
view channel
Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary
Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Blood Test Enables Early Detection and Classification of Glioma
High-grade gliomas, particularly glioblastoma, are fast-growing brain tumors that are often diagnosed late and typically require invasive procedures for confirmation. Current pathways rely on symptoms,... Read more
Multi-Biomarker Blood Test Detects Early-Stage Cancers Across Types
Abbott is showcasing its Cancerguard multi-cancer early detection (MCED) test at the American Association for Cancer Research (AACR) Annual Meeting 2026, where new data highlight continued progress in... Read more
New Sample-to-Answer PCR System Supports High-Throughput Infectious Disease Testing
Clinical laboratories face mounting demand for rapid, high‑volume molecular testing for infectious diseases, including routine monitoring in immunocompromised patients. Consolidated, sample‑to‑answer workflows... Read moreHematology
view channel
Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
Anemia detected in routine care can signal underlying pathology and is frequently encountered in adults. Because it is defined by hemoglobin levels below the normal range, it is often evaluated with red... Read more
Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
Chronic myelomonocytic leukemia (CMML) is a rare blood cancer in which acquired genetic mutations in bone marrow stem cells drive disease. Stem cell transplantation is the only curative option but carries... Read moreImmunology
view channel
Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
Immune aging undermines host defense and contributes to multiple age-related diseases, yet its heterogeneity complicates measurement and intervention. Clinical laboratories increasingly seek objective... Read more
Study Finds Influenza Often Undiagnosed in Winter Deaths
Seasonal influenza drives substantial excess mortality, yet its contribution is often obscured when infections go undiagnosed near the time of death. Many deaths occur outside hospitals or in older adults... Read moreMicrobiology
view channel
Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
Gram-negative bloodstream infections and sepsis demand fast, precise antimicrobial therapy, yet conventional susceptibility workflows can delay targeted treatment. Clinical laboratories need platforms... Read more
Antibiotic Resistance Genes Found in Newborns Within Hours of Birth
Antibiotic resistance in early life is challenging to characterize, particularly around the timing and drivers of gene acquisition in newborns. Meconium, the first stool passed by infants, was long considered... Read moreTechnology
view channel
AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more
Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read moreIndustry
view channel
QuidelOrtho Adds Ultra-Fast PCR Platform with LEX Acquisition
QuidelOrtho Corporation has completed the acquisition of LEX Diagnostics for approximately USD 100 million in cash. The transaction adds the LEX VELO System to QuidelOrtho’s portfolio. The platform received U.... Read more
Seegene Showcases Real-Time PCR Data Analytics Platform at ESCMID
Seegene introduced STAgora, a real-time data analytics platform built on aggregated statistical testing data, at ESCMID Global 2026 in Munich, where it also presented an enhanced model of its automated... Read more
Roche Affiliate Expands MRD Portfolio with SAGA Acquisition
Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more




.jpg)


